See the DrugPatentWatch profile for keytruda

Keytruda, a drug manufactured by Merck & Co., is primarily indicated for the treatment of several types of cancer. According to the drug's prescribing information, Keytruda is approved for use in patients with melanoma, lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancer, and merkel cell carcinoma [1].

The primary cancer indication for Keytruda is melanoma, which was the first indication for the drug when it was approved by the FDA in 2014 [2]. Keytruda is a programmed death receptor-1 (PD-1) blocking antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells [1].

It's worth noting that, according to DrugPatentWatch.com, Keytruda is expected to generate over $14 billion in sales by 2023, and it is one of the best-selling drugs in the world [3].

In summary, the primary cancer indication for Keytruda is melanoma, and it is also approved for the treatment of several other types of cancer. Keytruda is a PD-1 blocking antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells.

Sources:

[1] Keytruda (pembrolizumab) injection, for intravenous use, prescribing information, Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, 2021. <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>

[2] FDA approves new indication for Keytruda for treatment of advanced melanoma. FDA. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-indication-keytruda-treatment-advanced-melanoma>

[3] Keytruda Sales and Keytruda Patent. DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/keytruda.html>